MFSD11

Across TCGA pan-cancer cohorts, MFSD11 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MFSD11 data layer compared with 3 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MFSD11 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MFSD11 expression acts as an unfavorable survival marker, although some lineages such as KIRC and BRCA show a favorable association.

BLCA, LIHC, and KIRP are the cancer types where MFSD11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.320	0.515	<.001	99	view →
LIHC	DFS	Median	All	0.357	0.515	<.001	55	view →
KIRP	OS	Tertile	II,III,IV	0.120	0.887	.006	52	view →
LGG	DFS	Median	All	0.672	0.803	<.001	43	view →
KIRC	DFS	Median	All	0.742	0.509	<.001	28	view →
ACC	OS	Quartile	All	0.437	0.848	.006	26	view →
MESO	OS	Median	III,IV	0.452	0.685	.021	21	view →
BRCA	OS	Quartile	IV	0.828	0.219	.003	21	view →
UCEC	DFS	Quartile	All	0.415	0.755	.001	16	view →
STAD	DFS	Median	IV	0.180	0.559	.014	13	view →
UCS	OS	Tertile	IV	1.000	0.352	.036	12	view →
ESCA	DFS	Quartile	All	0.225	0.450	.015	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MFSD11–BLCA (OS)

Open the BLCA breakdown →